Tenderwize
Retour à la recherche

Medicinal product with the active substance Sevelamer hydrochloride (ATC: V03AE02)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Oct 30, 2026 · 63 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Sevelamer hydrochlorid (ATC: V03AE02)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed purchase volumes; contracts are non-exclusive, so actual revenue depends on market share and prescribing...

Buyer may terminate these contracts if exclusive agreements for the same active substance are awarded during the contra...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for Sevelamer hydrochloride (ATC: V03AE02)
  • Open-house model: anytime accession for all qualified pharmaceutical companies
Afficher le résumé complet

Non-exclusive discount agreements ('open-house model') for the pharmaceutical product Sevelamer hydrochloride (ATC: V03AE02) with the AOK Sachsen-Anhalt. Any qualifying pharmaceutical company can join at any time. The contract period is maximum 24 months from January 1, 2025 to December 31, 2026. Estimated contract value is not provided.

Risques

No guaranteed purchase volumes; contracts are non-exclusive, so actual revenue depends on market share and prescribing...

Buyer may terminate these contracts if exclusive agreements for the same active substance are awarded during the contra...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies

Administrative

  • Must request and submit participation documents fully completed and signed
  • Must comply with the uniform contract terms and conditions

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Open-house: all qualifying companies get a contract

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Medicinal product with the active substance Sevelamer hydrochloride (ATC: V03AE02)

Conclusion of non-exclusive discount agreements under §130a(8) SGB V for finished medicinal products containing Sevelamer hydrochloride. Open-house model with anytime accession; no exclusivity; contracts can be concluded at any time on identical terms; earliest start 01.01.2025, latest end 31.12.2026.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Critères d'attribution

Open-house: all qualifying companies get a contract

Date limite

Deadline Oct 30, 2026

Détails de la procédure

Date de publication
12 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
690399-2024

Documents (1)

Appels d'offres similaires